$CDXS
CODEXIS, INC.

2023 Q3 Form 10-Q Financial Statement

#000120037523000029 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $9.277M $21.32M
YoY Change -73.09% -44.48%
Cost Of Revenue $2.249M $3.178M
YoY Change -77.02% -71.8%
Gross Profit $7.028M $18.15M
YoY Change -71.53% -33.13%
Gross Profit Margin 75.76% 85.1%
Selling, General & Admin $12.30M $13.37M
YoY Change -8.87% 25.42%
% of Gross Profit 175.04% 73.66%
Research & Development $13.66M $17.33M
YoY Change -37.39% -9.19%
% of Gross Profit 194.39% 95.53%
Depreciation & Amortization $1.357M $1.480M
YoY Change -3.42% 10.37%
% of Gross Profit 19.31% 8.16%
Operating Expenses $25.96M $30.70M
YoY Change -26.49% 3.21%
Operating Profit -$32.06M -$12.63M
YoY Change 201.43% 383.94%
Interest Expense $1.060M $1.121M
YoY Change 143.12% 700.71%
% of Operating Profit
Other Income/Expense, Net -$3.895M -$9.000K
YoY Change -1903.24% -85.71%
Pretax Income -$34.90M -$11.51M
YoY Change 249.55% 354.74%
Income Tax $9.000K $9.000K
% Of Pretax Income
Net Earnings -$34.91M -$11.52M
YoY Change 249.36% 336.48%
Net Earnings / Revenue -376.29% -54.04%
Basic Earnings Per Share -$0.50 -$0.17
Diluted Earnings Per Share -$0.50 -$0.17
COMMON SHARES
Basic Shares Outstanding 69.80M shares 66.77M shares
Diluted Shares Outstanding 69.47M shares 67.57M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.60M $92.09M
YoY Change -31.36% 2.2%
Cash & Equivalents $74.60M $92.10M
Short-Term Investments
Other Short-Term Assets $7.000M $4.287M
YoY Change 18.44% -5.39%
Inventory $2.305M $2.052M
Prepaid Expenses
Receivables $19.10M $21.61M
Other Receivables $0.00 $0.00
Total Short-Term Assets $103.0M $120.0M
YoY Change -29.44% -17.37%
LONG-TERM ASSETS
Property, Plant & Equipment $15.28M $23.33M
YoY Change -34.47% -1.56%
Goodwill $2.463M $3.200M
YoY Change -23.03% 0.0%
Intangibles
YoY Change
Long-Term Investments $18.00M $21.38M
YoY Change -12.24% 10.76%
Other Assets $726.0K $498.0K
YoY Change 249.04% 122.32%
Total Long-Term Assets $51.44M $86.72M
YoY Change -42.39% -3.31%
TOTAL ASSETS
Total Short-Term Assets $103.0M $120.0M
Total Long-Term Assets $51.44M $86.72M
Total Assets $154.5M $206.8M
YoY Change -34.35% -12.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.098M $4.042M
YoY Change 18.2% 100.6%
Accrued Expenses $8.796M $7.001M
YoY Change -32.3% -45.87%
Deferred Revenue $9.236M $10.53M
YoY Change 476.53% 372.15%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.42M $35.74M
YoY Change 20.39% 19.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.219M $1.405M
YoY Change -10.1% 4.85%
Total Long-Term Liabilities $1.219M $1.405M
YoY Change -10.1% 4.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.42M $35.74M
Total Long-Term Liabilities $1.219M $1.405M
Total Liabilities $62.95M $82.63M
YoY Change -22.44% 9.43%
SHAREHOLDERS EQUITY
Retained Earnings -$490.3M -$455.4M
YoY Change 19.98% 14.23%
Common Stock $6.000K $6.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $91.51M $124.1M
YoY Change
Total Liabilities & Shareholders Equity $154.5M $206.8M
YoY Change -34.35% -12.01%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$34.91M -$11.52M
YoY Change 249.36% 336.48%
Depreciation, Depletion And Amortization $1.357M $1.480M
YoY Change -3.42% 10.37%
Cash From Operating Activities -$16.30M -$16.09M
YoY Change -182.6% 637.6%
INVESTING ACTIVITIES
Capital Expenditures $680.0K $1.581M
YoY Change -151.91% -181.45%
Acquisitions
YoY Change
Other Investing Activities -$420.0K $10.00K
YoY Change -42100.0% -103.58%
Cash From Investing Activities -$1.100M -$1.571M
YoY Change -15.97% -29.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -110.0K 6.923M
YoY Change -182.71% 2871.24%
NET CHANGE
Cash From Operating Activities -16.30M -16.09M
Cash From Investing Activities -1.100M -1.571M
Cash From Financing Activities -110.0K 6.923M
Net Change In Cash -17.51M -10.74M
YoY Change -194.35% 157.56%
FREE CASH FLOW
Cash From Operating Activities -$16.30M -$16.09M
Capital Expenditures $680.0K $1.581M
Free Cash Flow -$16.98M -$17.67M
YoY Change -180.69% 7261.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q2 us-gaap Assets Current
AssetsCurrent
120044000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
162894000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1530000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1521000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1405000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1371000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
82630000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
105596000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69804000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69804000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
579555000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
566081000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455430000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-421290000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
124131000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
144797000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
206761000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
250393000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21323000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3178000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11270000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17334000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19089000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13365000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10656000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
72000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
126016000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
141000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2716000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
331000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6781000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11523000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
124131000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
158635000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
251000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3174000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
57000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
18000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2640000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159459000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
144797000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5525000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
721000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7931000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
404000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34140000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
124131000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
164391000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
432000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6951000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
118000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1437000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10996000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159459000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10996000 usd
us-gaap Depreciation
Depreciation
2556000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2406000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7069000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-307000 usd
us-gaap Other Noncash Income
OtherNoncashIncome
245000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-15000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-27000 usd
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
-19261000 usd
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
10962000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
23000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
558000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1324000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1811000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
631000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-958000 usd
cdxs Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities
10373000 usd
cdxs Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities
-81000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2864000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2527000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9970000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-710000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25299000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13367000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4120000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7030000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
28000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
750000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
5300000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4855000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12302000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
422000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
432000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8652000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
395000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
42000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
404000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1437000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8275000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1047000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21879000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26716000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116026000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118895000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94147000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92179000 usd
us-gaap Interest Paid Net
InterestPaidNet
10000 usd
us-gaap Interest Paid Net
InterestPaidNet
12000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
193000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
434000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
409000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92093000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90113000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2054000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2066000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directed evolution platform.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we reported our financial results based on two reportable segments: Performance Enzymes and Novel Biotherapeutics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Performance Enzymes business consists primarily of two focus areas: i) biocatalysts for the sustainable manufacturing of pharmaceuticals and ii) enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. Our Novel Biotherapeutics business includes product candidates in clinical and preclinical development. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment information aligns with how the chief operating decision maker (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CODM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), who is our Chief Executive Officer (CEO), reviews and manages the business. In July 2023, we announced that we are discontinuing investment in Novel Biotherapeutics and expect to have just one business segment, Performance Enzymes, by the end of 2023.</span></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</span></div>
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21323000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21323000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21323000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34305000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34305000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
CY2023Q2 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
2248000 usd
CY2022Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
2116000 usd
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
10691000 usd
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
7016000 usd
CY2023Q2 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
0 usd
CY2022Q4 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
19000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
20639000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30609000 usd
CY2023Q2 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
CY2023Q2 cdxs Contract With Customer Liability Release Early Termination Of Obligation
ContractWithCustomerLiabilityReleaseEarlyTerminationOfObligation
2900000 usd
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
441000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7814000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1413000 usd
CY2023Q2 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
3356000 usd
CY2022Q2 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-298000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
3140000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-29000 usd
CY2023Q2 cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
11860000 usd
CY2022Q2 cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
38263000 usd
cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
23351000 usd
cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
72362000 usd
CY2023Q2 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
21323000 usd
CY2022Q2 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
38406000 usd
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
34305000 usd
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
73746000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
10409000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
9590000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
140000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
500000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
20639000 usd
CY2023Q2 cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
CY2022Q2 cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
21378000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
20510000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92100000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114000000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1200000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1200000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
65797000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
62435000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
42472000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39821000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23325000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22614000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
1480000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1341000 usd
us-gaap Depreciation
Depreciation
2946000 usd
us-gaap Depreciation
Depreciation
2556000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
3200000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
3200000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
3296000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
3495000 usd
CY2023Q2 us-gaap Purchase Obligation
PurchaseObligation
2884000 usd
CY2022Q4 us-gaap Purchase Obligation
PurchaseObligation
10852000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
821000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
932000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7001000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15279000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2716000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3231000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5525000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7069000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2716000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3231000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5525000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7069000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
214284 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
174600 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.47
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000 usd
CY2023Q1 cdxs Sale Of Stock Securities Registered Aggregate Amount
SaleOfStockSecuritiesRegisteredAggregateAmount
200000000 usd
CY2023Q2 cdxs Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
7100000 usd
cdxs Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
8700000 usd
CY2023Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
6800000 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
7900000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
CY2023Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
77300 sqft
CY2023Q2 cdxs Lessee Operating Lease Option To Extend Number
LesseeOperatingLeaseOptionToExtendNumber
1 renewal_option
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
500000 usd
CY2023Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
500000 usd
CY2023Q2 cdxs Finance Lease Cost
FinanceLeaseCost
0 usd
CY2022Q2 cdxs Finance Lease Cost
FinanceLeaseCost
0 usd
cdxs Finance Lease Cost
FinanceLeaseCost
0 usd
cdxs Finance Lease Cost
FinanceLeaseCost
18000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1830000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1829000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3660000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3660000 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
40000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
1830000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
1839000 usd
us-gaap Lease Cost
LeaseCost
3660000 usd
us-gaap Lease Cost
LeaseCost
3718000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
us-gaap Operating Lease Payments
OperatingLeasePayments
3775000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2817000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3793000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7783000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8004000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8232000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5835000 usd
CY2023Q2 cdxs Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
14870000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48517000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7512000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
41005000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5626000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35379000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
41005000 usd
CY2023Q2 us-gaap Other Commitment
OtherCommitment
5712000 usd
CY2023Q2 us-gaap Other Commitments Future Minimum Payments Remainder Of Fiscal Year
OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear
4804000 usd
CY2023Q2 cdxs Other Commitment To Be Paid Year One And Thereafter
OtherCommitmentToBePaidYearOneAndThereafter
908000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21323000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34305000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
CY2022Q1 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
163000 usd
CY2022Q4 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
163000 usd
CY2021Q4 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
416000 usd
CY2021Q1 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
416000 usd
CY2023Q2 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0 usd
CY2022Q2 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0 usd
cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
30000 usd
CY2023Q2 cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
30000 usd
CY2022Q2 cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
257000 usd
cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
257000 usd
cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
0 usd
CY2023Q2 cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
0 usd
cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
50000 usd
CY2022Q2 cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
50000 usd
CY2023Q2 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
133000 usd
CY2022Q2 us-gaap Allowance For Notes And Loans Receivable Current
AllowanceForNotesAndLoansReceivableCurrent
109000 usd
CY2023Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8806000 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
31904000 usd
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001200375-23-000029-index-headers.html Edgar Link pending
0001200375-23-000029-index.html Edgar Link pending
0001200375-23-000029.txt Edgar Link pending
0001200375-23-000029-xbrl.zip Edgar Link pending
cdxs-20230630.htm Edgar Link pending
cdxs-20230630.xsd Edgar Link pending
cdxs_20230630xex311.htm Edgar Link pending
cdxs_20230630xex312.htm Edgar Link pending
cdxs_20230630xex321.htm Edgar Link pending
certificateofamendmenttoni.htm Edgar Link pending
codexis2023employeestockpu.htm Edgar Link pending
cdxs-20230630_cal.xml Edgar Link unprocessable
cdxs-20230630_def.xml Edgar Link unprocessable
cdxs-20230630_lab.xml Edgar Link unprocessable
cdxs-20230630_pre.xml Edgar Link unprocessable
cdxs-20230630_htm.xml Edgar Link completed
codexisamendmentto2019ince.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable